Vanda Pharmaceuticals Inc. (VNDA)

16.82
0.49 2.83
NASDAQ
Prev Close 17.31
Open 17.22
Day Low/High 16.67 / 17.22
52 Wk Low/High 13.88 / 33.44
Volume 411.77K
Exchange NASDAQ
Shares Outstanding 52.64B
Market Cap 883.88M
Div & Yield N.A. (N.A)
EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Vanda Pharmaceuticals Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Vanda Pharmaceuticals Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Vanda Pharmaceuticals Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DHX, EWBC, KE, MSON, OMN, RDWR, RNR, SEE Downgrades: AR, FTAI, K, RYN, SNY, TWO, VNDA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Vanda Pharmaceuticals Takes A Stand Against Unnecessary Animal Research

Vanda Pharmaceuticals Takes A Stand Against Unnecessary Animal Research

Company pursuing legal action against the FDA for requiring unnecessary studies that would result in the death of dozens of dogs without legal authority.

First Week Of February 15th Options Trading For Vanda Pharmaceuticals (VNDA)

First Week Of February 15th Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application For Review In The Treatment Of Jet Lag Disorder

FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application For Review In The Treatment Of Jet Lag Disorder

WASHINGTON, Dec. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Announces Positive Pivotal Study Results For HETLIOZ® (tasimelteon) In Patients With Smith-Magenis Syndrome

Vanda Announces Positive Pivotal Study Results For HETLIOZ® (tasimelteon) In Patients With Smith-Magenis Syndrome

WASHINGTON, Dec. 10, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reaches Analyst Target Price

Vanda Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Vanda Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $29.40, changing hands for $31.47/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Vanda Announces Positive Phase II Study Results For Tradipitant In Patients With Gastroparesis

Vanda Announces Positive Phase II Study Results For Tradipitant In Patients With Gastroparesis

Management to host conference call on Monday, December 3 at 8:30 AM ET

First Week Of January 2019 Options Trading For Vanda Pharmaceuticals (VNDA)

First Week Of January 2019 Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options become available this week, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

Vanda Pharmaceuticals Announces Participation At November 2018 Investor Conferences

Vanda Pharmaceuticals Announces Participation At November 2018 Investor Conferences

WASHINGTON, Nov. 8, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results

Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results

-- Hetlioz® net product sales grew to $29.9 million in the third quarter of 2018, a 34% increase compared to the third quarter of 2017

Vanda Receives FDA Letter Regarding Corporate Webpage

Vanda Receives FDA Letter Regarding Corporate Webpage

WASHINGTON, Nov. 1, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AZPN, COG, FBP, GCAP, SPSC, TWTR, USAK, VNDA Downgrades: ALK, CCK, CRM, EIGI, FBHS, GWRE, HOFT, HOPE, LAWS, LEG, MAS, MRVL, VREX, VTR, WRK Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Interesting VNDA Put And Call Options For August 17th

Interesting VNDA Put And Call Options For August 17th

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

VNDA Makes Notable Cross Below Critical Moving Average

VNDA Makes Notable Cross Below Critical Moving Average

In trading on Friday, shares of Vanda Pharmaceuticals Inc crossed below their 200 day moving average of $15.29, changing hands as low as $15.15 per share. Vanda Pharmaceuticals Inc shares are currently trading down about 1.9% on the day.

First Week of February 2018 Options Trading For Vanda Pharmaceuticals (VNDA)

First Week of February 2018 Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

Interesting VNDA Put And Call Options For January 2018

Interesting VNDA Put And Call Options For January 2018

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.

Relative Strength Alert For Vanda Pharmaceuticals

Relative Strength Alert For Vanda Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Vanda Pharmaceuticals Enters Oversold Territory (VNDA)

Vanda Pharmaceuticals Enters Oversold Territory (VNDA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Vanda Pharmaceuticals (VNDA) Shares Cross Below 200 DMA

Vanda Pharmaceuticals (VNDA) Shares Cross Below 200 DMA

In trading on Thursday, shares of Vanda Pharmaceuticals Inc crossed below their 200 day moving average of $15.26, changing hands as low as $14.65 per share. Vanda Pharmaceuticals Inc shares are currently trading off about 5.5% on the day.

Interesting VNDA Put And Call Options For November 17th

Interesting VNDA Put And Call Options For November 17th

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Summit Therapeutics Stock Gets Smoked After IPO Pricing

Summit Therapeutics and Epizyme are raising cash to fund new drug development.

Vanda Pharmaceuticals (VNDA) Shares Cross Above 200 DMA

In trading on Tuesday, shares of Vanda Pharmaceuticals Inc crossed above their 200 day moving average of $15.01, changing hands as high as $15.30 per share. Vanda Pharmaceuticals Inc shares are currently trading up about 8.2% on the day.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADGE, ANTX, HY, RTRX, VNDA Downgrades: CELP, FORD, GRC, HMSY, LNCE, MET, NCI, OUT, PLPC, UBA Initiations: ADAP, DGLT Read on to get TheStreet Quant Ratings' detailed report:

First Week of May 19th Options Trading For Vanda Pharmaceuticals (VNDA)

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

VNDA Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of Vanda Pharmaceuticals Inc crossed below their 200 day moving average of $14.20, changing hands as low as $14.10 per share. Vanda Pharmaceuticals Inc shares are currently trading off about 1.4% on the day.

VNDA Crosses Below Key Moving Average Level

In trading on Thursday, shares of Vanda Pharmaceuticals Inc crossed below their 200 day moving average of $13.75, changing hands as low as $13.55 per share. Vanda Pharmaceuticals Inc shares are currently trading off about 1.1% on the day.

First Week of April 21st Options Trading For Vanda Pharmaceuticals

Investors in Vanda Pharmaceuticals Inc saw new options begin trading this week, for the April 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VNDA options chain for the new April 21st contracts and identified one put and one call contract of particular interest.

VNDA Crosses Below Key Moving Average Level

VNDA Crosses Below Key Moving Average Level

In trading on Monday, shares of Vanda Pharmaceuticals Inc crossed below their 200 day moving average of $13.24, changing hands as low as $13.00 per share. Vanda Pharmaceuticals Inc shares are currently trading off about 1.5% on the day.

TheStreet Quant Rating: C+ (Hold)